Pralsetinib + Cabozantinib + Vandetanib
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Medullary Thyroid Cancer
Conditions
Medullary Thyroid Cancer
Trial Timeline
Nov 30, 2023 → Apr 12, 2035
NCT ID
NCT04760288About Pralsetinib + Cabozantinib + Vandetanib
Pralsetinib + Cabozantinib + Vandetanib is a phase 3 stage product being developed by Roche for Medullary Thyroid Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04760288. Target conditions include Medullary Thyroid Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Medullary Thyroid Cancer were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04760288 | Phase 3 | Withdrawn |
Competing Products
9 competing products in Medullary Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selpercatinib + Cabozantinib + Vandetanib | Eli Lilly | Phase 3 | 44 |
| Selpercatinib | Eli Lilly | Phase 1/2 | 36 |
| • TF2 and 68 Ga-IMP-288 | Gilead Sciences | Phase 1/2 | 32 |
| Caprelsa | Sanofi | Pre-clinical | 26 |
| Vandetanib 300mg | Sanofi | Phase 1/2 | 32 |
| Vandetanib | Sanofi | Phase 3 | 40 |
| vandetanib + omeprazole + ranitidine | Sanofi | Phase 1 | 29 |
| Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule | Exelixis | Approved | 44 |
| cabozantinib | Exelixis | Pre-clinical | 23 |